The use of tissue-specific promoters to target cancer cells is not novel, having been demonstrated in multiple cancers, such as the cholecystokinin type A receptor promoter in colorectal cancer [20] or the HTERT promoter active in >90% of human cancers [21]. This evidence concerns the gene CCKAR and cancer.